Matches in Wikidata for { <http://www.wikidata.org/entity/Q58035802> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q58035802 description "im März 2014 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58035802 description "wetenschappelijk artikel" @default.
- Q58035802 description "наукова стаття, опублікована в березні 2014" @default.
- Q58035802 name "Sirolimus therapy for a patient with segmental overgrowth due to a mosaic activating mutation in phosphatidylinositol-3-kinase" @default.
- Q58035802 name "Sirolimus therapy for a patient with segmental overgrowth due to a mosaic activating mutation in phosphatidylinositol-3-kinase" @default.
- Q58035802 type Item @default.
- Q58035802 label "Sirolimus therapy for a patient with segmental overgrowth due to a mosaic activating mutation in phosphatidylinositol-3-kinase" @default.
- Q58035802 label "Sirolimus therapy for a patient with segmental overgrowth due to a mosaic activating mutation in phosphatidylinositol-3-kinase" @default.
- Q58035802 prefLabel "Sirolimus therapy for a patient with segmental overgrowth due to a mosaic activating mutation in phosphatidylinositol-3-kinase" @default.
- Q58035802 prefLabel "Sirolimus therapy for a patient with segmental overgrowth due to a mosaic activating mutation in phosphatidylinositol-3-kinase" @default.
- Q58035802 P1433 Q58035802-D40F0512-6C56-4FEC-8B92-F48553AF4756 @default.
- Q58035802 P1476 Q58035802-F6DBE6D9-B42D-41AE-BED5-005D0D41D0DA @default.
- Q58035802 P2093 Q58035802-189119FC-02B9-4828-86FF-193779589DE7 @default.
- Q58035802 P2093 Q58035802-630A7499-705D-486B-86B2-17CD26932294 @default.
- Q58035802 P2093 Q58035802-A45DA13C-4DAB-4CDA-99E9-8ADABD0341A0 @default.
- Q58035802 P2093 Q58035802-C089E7D2-6614-477A-95A7-F968D21F9729 @default.
- Q58035802 P2093 Q58035802-CBB67934-D09A-4CA1-B090-C0AC22969621 @default.
- Q58035802 P2093 Q58035802-EF59C6EC-0FD0-41B7-9EA9-B7850A23A262 @default.
- Q58035802 P2093 Q58035802-FF5AE143-9ED2-455E-922A-CE2B57DD05E3 @default.
- Q58035802 P31 Q58035802-F46023ED-FFC3-4931-BCCB-1B9948833A7C @default.
- Q58035802 P356 Q58035802-5252A523-035D-42F8-9FC2-DC13E1FD2445 @default.
- Q58035802 P50 Q58035802-56C51EC2-571F-4691-92D6-E519F0AFE873 @default.
- Q58035802 P50 Q58035802-BD9CDCF5-9A98-44C4-82BF-A267A743CA3E @default.
- Q58035802 P577 Q58035802-25C09FD2-991D-4738-A545-8E6E79FAB32D @default.
- Q58035802 P921 Q58035802-B33BC341-8F33-4823-A2A4-585F4C67B9EB @default.
- Q58035802 P356 ENDOABS.34.OC6.3 @default.
- Q58035802 P1433 Q53952632 @default.
- Q58035802 P1476 "Sirolimus therapy for a patient with segmental overgrowth due to a mosaic activating mutation in phosphatidylinositol-3-kinase" @default.
- Q58035802 P2093 "Felicity Payne" @default.
- Q58035802 P2093 "Ines Barroso" @default.
- Q58035802 P2093 "Iona Isaac" @default.
- Q58035802 P2093 "Julie Harris" @default.
- Q58035802 P2093 "Marjorie Lindhurst" @default.
- Q58035802 P2093 "Susan Huson" @default.
- Q58035802 P2093 "Victoria Parker" @default.
- Q58035802 P31 Q13442814 @default.
- Q58035802 P356 "10.1530/ENDOABS.34.OC6.3" @default.
- Q58035802 P50 Q30505023 @default.
- Q58035802 P50 Q65054829 @default.
- Q58035802 P577 "2014-03-01T00:00:00Z" @default.
- Q58035802 P921 Q32089 @default.